EUVIMEDEUVIMED entdecken
Crossref

Engineering Dimeric Prodrug Nanoparticles Co-Delivering Paclitaxel and Immune Checkpoint Inhibitor to Boost Chemo-Immunotherapy

Zhengyuan Xu, Biyou Zhang, Shaojin Lu, Xiujuan Xiang, Qing Pei, Chunsheng Xiao, Zhigang Xie

ACS Applied Nano Materials · 30.10.2026 · 9 (43) · 20300-20312

DOI: 10.1021/acsanm.6c03761 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Nano Materials, online erschienen am 18.10.2026. Verfasst von Zhengyuan Xu und 6 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Natural Science Foundation of Jilin Province, National Basic Research Program of China (973 Program), National Natural Science Foundation of China (NSFC).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of chemotherapy and immune checkpoint blockade-associated therapy shows great potential in combating malignant tumors. Nanodrug systems can effectively improve the delivery efficiency of chemotherapeutic and immune drugs. Herein, redox-responsive dimeric paclitaxel and bromodomain-containing protein 4 inhibitor prodrugs were synthesized and co-assembled into stable nanoparticles in the presence of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)2k]. After intravenous injection, the prepared nanodrugs can accumulate at tumors and respond to their redox microenvironment to release paclitaxel and an immune checkpoint inhibitor. The released paclitaxel can inhibit microtubule depolymerization to kill tumor cells, which also enhances immunogenic cell death, thereby promoting antitumor immune responses. In addition, this immune checkpoint inhibitor can effectively reduce the expression of programmed cell death ligand 1 to reverse the immune resistance, thus synergistically activating cytotoxicity T lymphocytes through remodeling the tumor immune microenvironment. As a result, these nanodrugs exhibit effective tumor suppression with alleviated systemic toxicity. This work provides valuable insight into constructing simple nanoplatforms to simultaneously deliver different therapeutics for effective tumor treatment.

Förderung

  • Natural Science Foundation of Jilin Province
  • National Basic Research Program of China (973 Program)
  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Xu, Z., Zhang, B., Lu, S., Xiang, X., Pei, Q., Xiao, C., & Xie, Z. (2026). Engineering Dimeric Prodrug Nanoparticles Co-Delivering Paclitaxel and Immune Checkpoint Inhibitor to Boost Chemo-Immunotherapy. ACS Applied Nano Materials, 9(43), 20300-20312. https://doi.org/10.1021/acsanm.6c03761

Vancouver

Xu Z, Zhang B, Lu S, Xiang X, Pei Q, Xiao C, et al. Engineering Dimeric Prodrug Nanoparticles Co-Delivering Paclitaxel and Immune Checkpoint Inhibitor to Boost Chemo-Immunotherapy. ACS Applied Nano Materials. 2026;9(43):20300-20312. doi:10.1021/acsanm.6c03761

BibTeX
@article{Xu2026,
  author = {Xu, Zhengyuan and Zhang, Biyou and Lu, Shaojin and Xiang, Xiujuan and Pei, Qing and Xiao, Chunsheng and Xie, Zhigang},
  title = {Engineering Dimeric Prodrug Nanoparticles Co-Delivering Paclitaxel and Immune Checkpoint Inhibitor to Boost Chemo-Immunotherapy},
  journal = {ACS Applied Nano Materials},
  year = {2026},
  volume = {9},
  number = {43},
  pages = {20300--20312},
  doi = {10.1021/acsanm.6c03761}
}
Kostenlos starten →